New trial evidence has shown that Kite’s CAR-T cell therapy Yescarta (axicabtagene ciloleucel: axi-cel) reduces the risk of death by 27.4% in patients with relapsed or refractory large B-cell lymphoma (R/R LBCL), corresponding to a 38% improvement in overall survival (OS). It is the only treatment in nearly 30 years… Read More
Don’t forget to register for the DDW Turning Science into Business Summit, ‘Cancer research opportunities and advances’, to hear insight and expertise from leading international figures. The event, which will be sponsored by Taconic Biosciences, will take place online on 16 November at 7AM… Read More
The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. With the first DDW Turning Science into Business Summit taking… Read More
News round-up for 6-10 November by DDW Digital Content Editor Diana Spencer. With the first DDW Turning Science into Business Summit taking place next week on the theme of Cancer Research, this dynamic area of drug discovery is my round-up focus again. Most… Read More
The Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting (SITC 2023) took place on 1-5 November 2023, at San Diego Convention Center in San Diego, US. CAN-2409 in non-metastatic pancreatic cancer Candel Therapeutics reported on initial positive interim data from its Phase II clinical trial… Read More
Listen to this article on the DDW Podcast: DDW Editor Reece Armstrong speaks to Christian Leisner, Chief Executive Officer of antibody therapeutics' developer CDR-Life about methods to increase access to antigens and improving immunotherapy treatments. RA: Why are existing immunotherapies restricted to certain patient populations? CL: Immunotherapies, principally anti-PD-1/-L1 checkpoint inhibitors,… Read More
The DDW Turning Science into Business Summit, ‘Cancer research opportunities and advances’ is a free summit offering expert thought leadership on cancer research, precision medicine and immunotherapy. Sponsored by Taconic, the event will take place online on 16 November at 7AM PST /… Read More
A new webinar ‘Selective degradation of cancer target WDR5 — Evaluation of PROTACs binary and ternary affinities with Spectral Shift‘, brought to you by NanoTemper, is now available to watch on-demand. As more and more R&D pipelines include PROTAC candidates — the race to bring successful and… Read More
As more and more R&D pipelines include PROTAC candidates — the race to bring successful and efficient protein degraders to the clinic is on. These targets present challenges in the biophysical characterisation of binary and ternary complexes, making developing effective degraders complicated. Watch this on-demand webinar to learn: How Spectral… Read More
Cancer Research UK and the KWF Dutch Cancer Society (KWF) have announced a new multi-project strategic partnership to advance promising therapeutic agents for cancer. Under the partnership, KWF intends to provide funding to enable the development of select early phase clinical programmes through Cancer Research UK’s Centre… Read More
Initial data from an ongoing Phase I/II study of HPK1 inhibitor NDI-101150 show clinical benefit in three patients with solid tumours, including one complete response in a patient with renal cell carcinoma. Two patients with pancreatic cancer and renal cell carcinoma, respectively, exhibited prolonged (> six… Read More
Register for the DDW Turning Science into Business Summit, ‘Cancer research opportunities and advances’, to hear insight and expertise from leading figures. It will be hosted by DDW and sponsored by Taconic Biosciences. The event will take place online on 16 November at 7AM… Read More
The European Society for Medical Oncology Meeting (ESMO) 2023 took place from 20-24 October in Madrid, Spain. Many drug discovery companies took the opportunity to share their latest cancer research findings. Axicabtagene ciloleucel, Kite Two indirect comparative analyses of CAR T-cell therapy axicabtagene ciloleucel vs. bispecific… Read More
UK regulatory authorities have approved the first trial of a gene therapy for young children with Hunter syndrome. The UK Medicines and Healthcare Products Regulatory Agency (MHRA), Research Ethics Committee (REC), and Health Research Authority (HRA) have all approved the clinical trial application that was submitted by The University of… Read More
The DDW Turning Science into Business Summit, ‘Cancer research opportunities and advances’ will take place online on 16 November at 7AM PDT / 10AM EDT / 3PM GMT / 4PM CET and will be available on-demand after that date. The free… Read More
The MHRA has granted conditional marketing authorisation for Tepkinly (epcoritamab) as a bispecific treatment for adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The conditional marketing authorisation for Great Britain is based on the single-arm Phase I/II EPCORE NHL-1 trial… Read More
